Prevention of infectious disease by neonatal and early infantile immunization: Prospects for the new millennium

Infectious Diseases in Clinical Practice

Volumn 10, Issue 4, 2001, Pages 199-204

  Marchant, Arnaud ^a   Newport, Melanie ^b  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; BCG VACCINE; CHOLERA TOXIN; CYTOKINE; DINUCLEOTIDE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID; DNA VACCINE; ENTEROTOXIN; FREUND ADJUVANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERLEUKIN 12; INTERLEUKIN 2; LIPOPOLYSACCHARIDE; LIPOSOME; LIVE VACCINE; MENINGOCOCCUS VACCINE; PEPTIDE; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; POLYGLACTIN; RECOMBINANT PROTEIN; SAPONIN; TETANUS TOXOID;

BCG VACCINATION; CHILD CARE; COST BENEFIT ANALYSIS; CPG ISLAND; DISEASE SEVERITY; DNA VECTOR; DRUG INDUCED DISEASE; GENE THERAPY; GENETIC ANALYSIS; GENETIC VARIABILITY; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFECTION CONTROL; INFECTION PREVENTION; NEWBORN INFECTION; NEWBORN TETANUS; PASSIVE IMMUNIZATION; PRENATAL CARE; REVIEW;

EID: 0034791288     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-200105000-00005     Document Type: Review

References (46)

1. Poliomyelitis as a paradigm for investment in and success of vaccination programs
2. Conclusions from the WHO multicenter study of serious infections in young infants
3. Infectious disease in early life in industrialised countries
4. Science, medicine, and the future: Vaccines and vaccination
5. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood
6. Fetal immunization of baboons induces a fetal-specific antibody response
7. Deficiency of the humoral immune response to measles vaccine in infants immunized at 6 months of age
8. Vaccination in the neonatal period and early infancy
9. Poor serologic responses five to seven years after immunization with high and standard titer measles vaccines
10. Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa
11. Neonatal and early life immune reponses to various forms of vaccine antigens qualitatively differ from adult responses: Predominance of a Th2-biased pattern which persists after adult boosting
12. IL-12 is a potent neonatal vaccine adjuvant
13. Neonatal tolerance revisited: Turning on newborn T cells with dendritic cells
14. Influence of HIV-infected maternal environment on development of infant IL-12 production
15. Newborns develop a Th1-type immune response to Mycobacterium bovis baccilus Calmette-Guerin vaccination
16. Helminth- and Bacillus Calmette-Guerin-induced immunity in children sensitized in utero to filariasis and schistosomiasis
17. IL-12, IFN-γ and T cell proliferation to measles in immunized infants
18. Ex vivo analysis of cytotoxic T lymphocytes to measles antigens during infection and after vaccination in Gambian children
19. T-cell function in newborn mice and humans
20. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection
21. The use of tetanus toxoid for the prevention of tetanus neonatorum: Final report of a double-blind controlled field trial
22. Maternal immunization for the prevention of bacterial infection in young infants
23. Maternal immunization against viral disease
24. Influence of maternal antibodies on vaccine responses: Inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice
25. Vaccine strategies to overcome maternal antibody mediated inhibition of measles vaccines
26. Early immunization with conjugate vaccines
27. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine for prevention of pneumonia and meningitis in Gambian infants
28. Haemophilus influenzae type b meningitis in The Gambia after introduction of a conjugate vaccine
29. Pneumococcal conjugate vaccines
30. Neonatal immunization: Response to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine
31. Advances in vaccine adjuvants
32. CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to redirect Th2 responses established by neonatal priming
33. Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: Infuence of adjuvants and maternal antibodies
34. Induction of Th1 and Th2 immunity in neonatal mice
35. CD40 ligation prevents neonatal induction of transplantation tolerance
36. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins
37. Optimism over vaccines administered via mucosal route
38. Bacterial toxins as mucosal adjuvants
39. Factors associated with the development of neonatal tolerance after the administration of a plasmid DNA vaccine
40. DNA immunization circumvents deficient induction of helper type 1 and cytotoxic T lymphocyte responses in neonates and during early life
41. Combining DNA and protein vaccines for early life immunization against respiratory syncytial virus in mice
42. DNA immunization of infants: Potential and limitations
43. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen
44. A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes
45. Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity
46. Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri vector